Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open-label trial

Background: In critically ill patients, antibiotic therapy is of great importance but long duration of treatment is associated with the development of antimicrobial resistance. Procalcitonin is a marker used to guide antibacterial therapy and reduce its duration, but data about safety of this reduction are scarce. We assessed the efficacy and safety of procalcitonin-guided antibiotic treatment in patients in intensive care units (ICUs) in a health-care system with a comparatively low use of antibiotics. Methods: We did a prospective, multicentre, randomised, controlled, open-label intervention... Mehr ...

Verfasser: de Jong, Evelien
van Oers, Jos A.
Beishuizen, Albertus
Vos, Piet
Vermeijden, Wytze J.
Haas, Lenneke E.
Loef, Bert G.
Dormans, Tom
van Melsen, Gertrude C.
Kluiters, Yvette C.
Kemperman, Hans
van den Elsen, Maarten J.
Schouten, Jeroen A.
Streefkerk, Jörn O.
Krabbe, Hans G.
Kieft, Hans
Kluge, Georg H.
van Dam, Veerle C.
van Pelt, Joost
Bormans, Laura
Otten, Martine Bokelman
Reidinga, Auke C.
Endeman, Henrik
Twisk, Jos W.
van de Garde, Ewoudt M.W.
de Smet, Anne Marie G.A.
Kesecioglu, Jozef
Girbes, Armand R.
Nijsten, Maarten W.
de Lange, Dylan W.
Dokumenttyp: Artikel
Erscheinungsdatum: 2016
Schlagwörter: NCT01139489 / antibiotic agent / C reactive protein / procalcitonin / adult / antibiotic therapy / article / clinical protocol / controlled study / critically ill patient / disease severity / drug efficacy / drug safety / female / human / immunoassay analyzer / infection / intensive care unit / major clinical study / male / mortality / multicenter study / Netherlands / open study / outcome assessment / practice guideline / priority journal / prospective study / randomized controlled trial / sepsis / septic shock / treatment duration / treatment outcome / Taverne
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27220035
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://dspace.library.uu.nl/handle/1874/336993

Background: In critically ill patients, antibiotic therapy is of great importance but long duration of treatment is associated with the development of antimicrobial resistance. Procalcitonin is a marker used to guide antibacterial therapy and reduce its duration, but data about safety of this reduction are scarce. We assessed the efficacy and safety of procalcitonin-guided antibiotic treatment in patients in intensive care units (ICUs) in a health-care system with a comparatively low use of antibiotics. Methods: We did a prospective, multicentre, randomised, controlled, open-label intervention trial in 15 hospitals in the Netherlands. Critically ill patients aged at least 18 years, admitted to the ICU, and who received their first dose of antibiotics no longer than 24 h before inclusion in the study for an assumed or proven infection were eligible to participate. Patients who received antibiotics for presumed infection were randomly assigned (1:1), using a computer-generated list, and stratified (according to treatment centre, whether infection was acquired before or during ICU stay, and dependent on severity of infection [ie, sepsis, severe sepsis, or septic shock]) to receive either procalcitonin-guided or standard-of-care antibiotic discontinuation. Both patients and investigators were aware of group assignment. In the procalcitonin-guided group, a non-binding advice to discontinue antibiotics was provided if procalcitonin concentration had decreased by 80% or more of its peak value or to 0·5 μg/L or lower. In the standard-of-care group, patients were treated according to local antibiotic protocols. Primary endpoints were antibiotic daily defined doses and duration of antibiotic treatment. All analyses were done by intention to treat. Mortality analyses were completed for all patients (intention to treat) and for patients in whom antibiotics were stopped while being on the ICU (per-protocol analysis). Safety endpoints were reinstitution of antibiotics and recurrent inflammation measured by C-reactive protein ...